archive_header_en_20251203154432269.png

icon_20251203182619268.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

<br>Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

The past, present and future of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab.

At the 143rd Annual Meeting of the Pharmaceutical Society of Japan, the organizing committee members, Prof. Matsuda, Prof. Ogawa and Prof. Maenaka planned "Theme 2: Antibody Therapeutics and Immunology" as an interdisciplinary program "Connecting and Surpassing". Speakers who are conducting original research in the fields of immunology, drug discovery science, analytical chemistry, protein science, structural biology and virology are scheduled to give talks of advanced research on "antibody drugs and immunity", which are very important from the aspects of drug discovery and medical treatment methods. The first half of this program will focus on antibody therapeutics, with session 1 focusing on the development of approved antibody therapeutics (Opdivo and antibody-drug conjugate ADCs) in companies (Dr. Wagatsuma, Dr. Yoshida), as well as the basics of antibody therapeutics (Prof. Tsumoto) and the development process and prospects of antibody therapeutics (Dr. Ishii) will be introduced. Furthermore, Dr Hisataka Kobayashi (NIH) will give a special lecture on state-of-the-art photodiagnostic therapy. The second half of the day will comprise Session 2 on immune mechanisms, with Prof. Shizuo Akira (Research Institute for Microbial Diseases, Osaka University) giving a special lecture on the latest regulatory mechanisms of Toll-like receptors (TLR) signaling. The symposium in session 2 will introduce cytokine signaling (Prof. Yoshimura), structural analysis of TLRs (Prof. Shimizu), intestinal bacteria (Prof. Hase) and interferon responses (Prof. Takaoka). Through the two special lectures and symposia, the results of cutting-edge research will be widely shared from the perspective of antibody therapeutics and immunology, which will hopefully provide an impetus for new drug discovery and therapeutics, and lead to the development of pharmaceutical sciences.

The Pharmaceutical Society of Japan

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

[ISS02-04]The past, present and future of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab.

Password required to view